ArticleEuropean journal of clinical pharmacology2007
Characterizing early prescribers of newly marketed drugs in Canada: a population-based study.
Article in European journal of clinical pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Factors affecting the uptake of new medicines: a systematic literature review.BMC health services research · 2014Pooled it
- Socioeconomic aspects of incretin-based therapy.Diabetologia · 2023Review
- Real-World Effects of Second-Generation Versus Earlier Intermediate/Basal Insulin Analogues on Rates of Hypoglycemia in Adults with Type 1 and 2 Diabetes (iNPHORM, US).Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- Marketing of medicines in primary care: An analysis of direct marketing mailings and advertisements.PloS one · 2023Article
- Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study.The British journal of general practice : the journal of the Royal College of General Practitioners · 2022Article
- Association between physician adoption of a new oral anti-diabetic medication and Medicare and Medicaid drug spending.BMC health services research · 2019Article
- Article
- Who Were the Early Adopters of Dabigatran?: An Application of Group-based Trajectory Models.Medical care · 2016Article
- Article
- In with the new: the determinants of prescribing innovation by general practitioners in Ireland.The European journal of health economics : HEPAC : health economics in prevention and care · 2012Article
- Adoption of new drugs by physicians: a survival analysis.BMC health services research · 2012Article
- Characteristics of primary health care units with focus on drug information from the pharmaceutical industry and adherence to prescribing objectives: a cross-sectional study.BMC clinical pharmacology · 2010Article
- Therapeutic traditions, patient socioeconomic characteristics and physicians' early new drug prescribing--a multilevel analysis of rosuvastatin prescription in south Sweden.European journal of clinical pharmacology · 2009Article
- Patient educational level and use of newly marketed drugs: a register-based study of over 600,000 older people.European journal of clinical pharmacology · 2008Article
- Lipid-lowering drug use in Italian primary care: effects of reimbursement criteria revision.European journal of clinical pharmacology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe diffusion of innovations model proposes that early adopters of innovation influence others. This study was undertaken to determine if early prescribers and users of newly marketed drugs had different sociodemographic and professional characteristics as compared to majority and late users and prescribers.
methodsAfter market availability in Manitoba, Canada, of celecoxib, alendronate, clopiodogrel and pantoprazole, time to first prescriptions was determined. Early, majority and late adopters of the new drug were characterized by this diffusion time. The prescription, health and prescriber records were compared across adopter categories. The likelihood of being an early or late prescriber or user of the new medications according to patient demographic characteristics, physician factors (specialty and place of training) and neighborhood income was determined with polytomous logistic regression.
resultsCelecoxib demonstrated a much more rapid uptake into routine use than the other drugs. More than 300 Manitoba physicians prescribed celecoxib within two weeks of market availability. Early prescribers of celecoxib were more likely than majority prescribers to be general practitioners (OR = 1.81, 95%CI: 1.40-2.35) and have hospital affiliations (OR = 1.35, 95%CI: 1.03-1.77). Early users of celecoxib were more likely than the majority to have arthritic conditions, have a high income and have paid out-of-pocket for their prescription. For alendronate, clopidogrel and pantoprazole, only prescription drug coverage predicted adopter category. Early prescribers of one new drug were not early prescribers of the other new drugs.
conclusionNo common group of patients or physicians who were early prescribers or users of all four medications was described.
Indexed as
Identifiers
17380324What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.